Materials for Healthcare Professionals:

	Take comfort in your protection This informative brochure contains information about the role of hormones in your health, hormone therapy, and PROMETRIUM®. To download, click here.
	Bio-identical Hormone Therapy: Is It natural? Is It better? This informative booklet from MenopauseRx.com[SM] addresses the differences between FDA-approved bio-identical hormones and compounded bio-identical hormones. To download, click here. Learn more at [SM]
	If you would like to order either of the brochures above for your office at no charge, please click here.
	PROMETRIUM® Full Prescribing Information Click here to download PROMETRIUM® Full Prescribing Information.

To view the file, you must have Adobe® Acrobat® installed on your computer. If you do not currently have Acrobat® Reader® installed on your computer, click on the link below for a free download from the Adobe® Web site.

Adobe® Reader® is a registered trademark of Adobe Systems Incorporated.

IMPORTANT SAFETY INFORMATION

Estrogens plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia. The Women’s Health Initiative (WHI) study reported increased risks of stroke, deep vein thrombosis (DVT), pulmonary embolism, myocardial infarction, and invasive breast cancer in postmenopausal women (ages 50–79 years) during 5.6 years of treatment with daily conjugated estrogens 0.625 mg combined with medroxyprogesterone acetate (MPA) 2.5 mg relative to placebo. The WHI Memory Study, an ancillary study of WHI, reported an increased risk of probable dementia in postmenopausal women 65 years of age or older.[1]

PROMETRIUM® is contraindicated for patients with any of the following conditions: known hypersensitivity to its ingredients; undiagnosed abnormal genital bleeding; known, suspected, or history of breast cancer; active deep vein thrombosis, pulmonary embolism or history of these conditions; active arterial thromboembolic disease (i.e. stroke, myocardial infarction) or a history of these conditions; known liver disease or dysfunction; known or suspected pregnancy.[1]

PROMETRIUM® is contraindicated in patients with known or suspected pregnancy.[1]

Pregnancy Category B

PATIENTS WHO ARE ALLERGIC TO PEANUTS SHOULD NOT USE PROMETRIUM® CAPSULES.[1]

The most common adverse events reported at a rate greater than placebo in a clinical trial by postmenopausal women receiving conjugated estrogens 0.625 mg daily plus cyclic PROMETRIUM® 200 mg capsules were: headache, breast tenderness, depression, dizziness, abdominal bloating, chest pain, and diarrhea.[1]

The most common adverse events reported at a rate greater than placebo in a clinical trial by postmenopausal women receiving PROMETRIUM® 400 mg capsules were: dizziness, abdominal pain, headache, breast pain, musculoskeletal pain, and viral infection.[1]

You are encouraged to report suspected adverse reactions. Please contact Solvay Pharmaceuticals, Inc. at 1-800-241-1643 or the FDA at www.fda.gov/medwatch or by calling 1-800-FDA-1088.

Please click here for the PROMETRIUM® Full Prescribing Information.

Reference:
1. PROMETRIUM® [package insert]. Marietta, Ga: Solvay Pharmaceuticals, Inc.; 2009.